Pharma BD Deal Intelligence
Astellas / Seattle Genetics (Padcev collaboration): Achieved Stated Rationale (Score: 87/100)
Full analysis, sources & comparables →Seattle Genetics and Astellas announced a clinical trial collaboration with Merck to evaluate enfortumab vedotin in combination with Keytruda in patients with…
Seagen and Astellas win expanded FDA approval for bladder cancer drug Padcev, further establishing the ADC as a cornerstone of urothelial cancer treatment.
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Astellas and Seattle Genetics (now Seagen) formed a global collaboration to develop enfortumab vedotin (Padcev), a Nectin-4 targeting ADC for urothelial cancer. The multi-year collaboration involved shared development costs and co-commercialization. Padcev was approved by FDA in 2019 and expanded to first-line use with Keytruda in 2023, generating >$3.4B in sales by 2024. Pfizer acquired Seagen in 2023 inheriting co-commercialization rights.
Astellas / Seattle Genetics (Padcev collaboration): Achieved Stated Rationale (Score: 87/100)
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Astellas Pharma Inc. / Seagen Inc. (this deal) | 2009 | $4.5B | 95 |
| Astellas Pharma Inc. / Ganymed Pharmaceuticals | 2016 | $1.4B | 81 |
| Astellas Pharma Inc. / Sangamo Therapeutics, Inc. | 2026 | $50M | 63 |
| Astellas Pharma Inc. / Ogeda SA | 2017 | $850M | 59 |
| Astellas Pharma Inc. / Ocata Therapeutics, Inc. | 2015 | $379M | 41 |
| Astellas Pharma Inc. / Optimer Pharmaceuticals, Inc. | 2012 | $90M | 38 |
| Astellas Pharma Inc. / OSI Pharmaceuticals | 2010 | $4.0B | 33 |
← Browse all deals · How we score deals
More: 2009 deals · Astellas Pharma Inc. deals · Oncology deals